Gilead increases Q2 revenue 13% and pumps up HCV R&D
10:06 EDT 27 Jul 2012 | SCRIP
Gilead Sciences' reported second quarter 2012 revenue that beat analyst expectations on 26 July and said the company will initiate a Phase III clinical trial before the end of this year to test one of its hepatitis C virus (HCV) therapies.....
Original Article: Gilead increases Q2 revenue 13% and pumps up HCV R&D
More From BioPortfolio on "Gilead increases Q2 revenue 13% and pumps up HCV R&D"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
